Dyne Therapeutics announced the pricing of an upsized underwritten public offering of 18,300,000 shares of common stock at $20.50 per share, with expected gross proceeds of $375,150,000 before underwriting discounts, commissions, and offering expenses.
The offering, in which all shares are being sold by Dyne, is expected to close on or about July 23, 2026, subject to customary closing conditions. Dyne has also granted underwriters a 30-day option to purchase up to an additional 2,745,000 shares at the public offering price, less underwriting discounts and commissions.
Morgan Stanley, Jefferies, and Evercore ISI are serving as joint book-running managers for the offering, along with LifeSci Capital and Raymond James, with Jones serving as lead manager. The offering is being made under a shelf registration statement on Form S-3 filed with the SEC on March 5, 2024, which became automatically effective upon filing.
Dyne Therapeutics is a clinical-stage company focused on delivering functional improvement for people with genetically driven neuromuscular diseases, with clinical programs targeting Duchenne muscular dystrophy and myotonic dystrophy type 1, along with preclinical programs addressing facioscapulohumeral muscular dystrophy, Pompe disease, and multiple Duchenne muscular dystrophy mutations.
